// App-Quantinova.ai

: A Retrospective Analysis of Prophylactic G-CSF Biosimilar and Originator Administrative Claims over Time Among Patients with Non-Hodgkin Lymphoma

Researchers

Presenter

  • Pamala A. Pawloski

Principal Investigators

  • Cara L. McDermott

  • GABRIELA VAZQUEZ BENITEZ

  • Terese A. DeFor

  • Aaron B. Mendelsohn

  • James Marshall

  • Erick Moyneur

  • Catherine M. Lockhart

Medical Centers

  • Harvard Pilgrim Healthcare Institute, Boston, MA

  • Biologics and Biosimilars Collective Intelligence Consortium, Alexandria, VA

  • StatLog, Montreal, Canada

  • HealthPartners Institute, Bloomington, MN

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Neutropenia

  • Lymphomas

Biomarkers

  • Granulocyte colony-stimulating factor

Drug/Treatment

  • Pegfilgrastim biosimilar

  • doxorubicin + etoposide

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Filgrastim-Sndz

  • Tbo-filgrastim

  • Pegfilgrastim

  • Bendamustine

  • Vinblastine

  • Vincristine

  • Doxorubicin

  • Filgrastim

  • Etoposide

  • Etoposide phosphate

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved